Content about Ustekinumab

March 31, 2014

Just days after the Food and Drug Administration approved Otezla, a new oral therapy to treat active psoriatic arthritis in adult patients, Avella Specialty Pharmacy on Friday announced that it is prepared to begin distributing the drug.

PHOENIX — Just days after the Food and Drug Administration approved Otezla, a new oral therapy to treat active psoriatic arthritis in adult patients, Avella Specialty Pharmacy on Friday announced that it is prepared to begin distributing the drug. 

At this time, Avella is one of a select number of pharmacies that are contracted by Celgene, the drug manufacturer, to dispense the product at launch.

September 23, 2013

The Food and Drug Administration has approved a drug made by Johnson & Johnson for psoriatic arthritis, the company said Monday.

HORSHAM, Pa. — The Food and Drug Administration has approved a drug made by Johnson & Johnson for psoriatic arthritis, the company said Monday.

Janssen Biotech, a subsidiary of J&J, announced the approval of Stelara (ustekinumab) alone or combined with the common generic drug methotrexate for treating active psoriatic arthritis in adults. According to the National Psoriasis Foundation, the autoimmune disease is estimated to affect more than 2 million people in the United States and is characterized by joint inflammation and psoriasis skin lesions.

April 16, 2013

Johnson & Johnson's sales increased by 8.5% to $17.5 billion in first quarter 2013, the healthcare products company said Tuesday.

NEW BRUNSWICK, N.J. — Johnson & Johnson's sales increased by 8.5% to $17.5 billion in first quarter 2013, the healthcare products company said Tuesday.

The increase included a domestic sales increase of 11.2%. Profits for the quarter were $3.5 billion.

December 6, 2012

Johnson & Johnson is seeking approval from the Food and Drug Administration for a drug to treat active psoriatic arthritis, the company said Thursday.

HORSHAM, Pa. — Johnson & Johnson is seeking approval from the Food and Drug Administration for a drug to treat active psoriatic arthritis, the company said Thursday.

J&J subsidiary Janssen Biotech submitted an application to the FDA for Stelara (ustekinumab) for adult patients with the disease, which affects more than 2 million people in the United States, according to the National Psoriasis Foundation. Another subsidiary is seeking approval for Stelara for the same usage in Europe.

August 23, 2012

A division of Johnson & Johnson has started a late-stage clinical trial program for a drug for rheumatoid arthritis under a partnership with British drug maker GlaxoSmithKline.

SPRING HOUSE, Pa. — A division of Johnson & Johnson has started a late-stage clinical trial program for a drug for rheumatoid arthritis under a partnership with British drug maker GlaxoSmithKline.

February 4, 2011

A drug used to treat inflammatory diseases improved the conditions of patients with psoriasis that affected the scalp compared with placebo, according to results of a new study.

THOUSAND OAKS, Calif. — A drug used to treat inflammatory diseases improved the conditions of patients with psoriasis that affected the scalp compared with placebo, according to results of a new study.

Amgen and Pfizer on Friday announced the results of the phase-4 study of Enbrel (etanercept), in patients with moderate to severe plaque psoriasis with scaling on the scalp, also known as scalp involvement. Data from the trial will be presented Friday at the 69th annual meeting of the American Academy of Dermatology in New Orleans.

February 21, 2010

The high prices of drugs made by Johnson & Johnson and Abbott will drive the...